AKT1 Gene Cowden Syndrome Type 6 NGS Genetic DNA Test
Comprehensive Genetic Testing for Inherited Cancer Risk
The AKT1 Gene Cowden Syndrome Type 6 NGS Genetic DNA Test represents a breakthrough in personalized cancer risk assessment. This advanced genetic screening utilizes Next-Generation Sequencing (NGS) technology to analyze the AKT1 gene for mutations associated with Cowden syndrome, a rare hereditary condition that significantly increases an individual’s lifetime risk for developing multiple types of cancer. Understanding your genetic predisposition to cancer can be life-saving, enabling proactive medical management and early detection strategies.
What Does the AKT1 Gene Cowden Syndrome Test Measure?
This comprehensive genetic test specifically targets the AKT1 gene, which plays a critical role in regulating cell growth and division. When mutations occur in this gene, they can lead to uncontrolled cell proliferation and increased cancer susceptibility. The test detects:
- Pathogenic variants in the AKT1 gene associated with Cowden syndrome
- Single nucleotide polymorphisms (SNPs) that may impact cancer risk
- Copy number variations affecting gene function
- Novel mutations that may not be documented in existing databases
Who Should Consider This Genetic Test?
This test is particularly recommended for individuals who exhibit:
- Personal history of multiple cancers, especially breast, thyroid, or endometrial cancer
- Family history of Cowden syndrome or related cancers
- Multiple benign tumors or hamartomas
- Characteristic physical features of Cowden syndrome (macrocephaly, mucocutaneous lesions)
- Unexplained developmental delays or autism spectrum disorders
- Early-onset cancers in the family
Clinical Benefits of AKT1 Genetic Testing
Undergoing the AKT1 Gene Cowden Syndrome Type 6 NGS Genetic DNA Test provides numerous advantages:
- Personalized Cancer Screening: Results enable tailored screening protocols based on individual genetic risk
- Early Detection: Identifies cancer predisposition before symptoms develop
- Family Planning: Provides crucial information for reproductive decisions
- Preventive Strategies: Allows implementation of risk-reduction measures
- Peace of Mind: Reduces uncertainty about inherited cancer risk
- Medical Management: Guides appropriate surveillance and intervention timing
Understanding Your Test Results
Your genetic test results will fall into one of several categories:
- Positive Result: Indicates the presence of a known pathogenic mutation in the AKT1 gene, confirming Cowden syndrome diagnosis and requiring enhanced cancer surveillance
- Negative Result: No mutation detected in the AKT1 gene, though other genetic factors may still contribute to cancer risk
- Variant of Uncertain Significance (VUS): Identifies a genetic change with unknown clinical significance, requiring ongoing monitoring and research
- Benign Variant: Common genetic variations not associated with increased cancer risk
All results are accompanied by comprehensive genetic counseling to ensure proper interpretation and development of personalized management plans.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| AKT1 Gene Cowden Syndrome Type 6 NGS Genetic DNA Test | $500 USD | $700 USD |
Nationwide Testing Availability
We have conveniently located testing centers across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our state-of-the-art facilities ensure accurate sample collection and processing with minimal wait times.
Take Control of Your Health Today
Don’t wait to understand your genetic cancer risk. The AKT1 Gene Cowden Syndrome Type 6 NGS Genetic DNA Test provides crucial information that can guide your healthcare decisions and potentially save lives. Our team of genetic counselors and oncology specialists are ready to support you through every step of the testing process.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your appointment and take the first step toward personalized cancer risk management.
Test turnaround time: 3 to 4 weeks
Sample type: Blood
Pre-test requirements: Clinical history and genetic counseling session
